We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. Amneal Pharmaceuticals, Inc. is one of them. Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) continues to strengthen its position in generic, branded, and specialty medicines, marking September 2025 with key regulatory milestones and financial progress. On September 26, AMRX submitted a Biologics License Application (BLA) for a biosimilar to XOLAIR® (omalizumab), targeting a multi-billion-dollar market that includes asthma, c ...

We recently compiled a list of the 12 Healthcare Stocks with Insider Buying in 2025. BGM Group Ltd. is one of them. BGM Group Ltd. (NASDAQ:BGM), a China-based pharmaceutical and chemical company, is rapidly transforming into an AI- and biopharma-focused enterprise. Through subsidiaries, the company develops specialty and generic drugs while expanding into intelligent robotics and healthcare technology. In 2025, BGM reported a 271% surge in total assets to $207.4 million as of March 31, fueled by acquisit ...

Key Points Novo Nordisk has a significant presence in the U.S. manufacturing sector and is expanding its facility. The administration won't impose tariffs until negotiations are closed. The drugmaker is awaiting approval to market an oral medication for weight loss. 10 stocks we like better than Novo Nordisk › Shares in Novo Nordisk (NYSE: NVO) were up 6% by 11:30 a.m. on Wednesday. The move comes after Pfizer's agreement with the Trump administration raised hopes that other pharmaceutical compan ...

Pfizer Inc. (NYSE:PFE) is included among the 10 Highest Dividend-Paying Stocks to Buy in the S&P 500. Pfizer (PFE): A Healthcare Giant Offering Steady Dividend Income Pfizer Inc. (NYSE:PFE) is a US pharmaceutical and biotech giant that provides various allied products and services to its customers. In recent years, the company has made several moves to fill its drug pipeline, most notably its $43 billion acquisition of Seagen, a cancer-focused company. The pharmaceutical behemoth is, meanwhile, mirroring ...

Pfizer (NYSE:PFE) shares are finally starting to attract attention after gaining close to 7% in a single trading session on news that it's reached a pricing deal with the Trump administration. ...

美股市场整体表现 - 标普500指数、道琼斯指数和纳斯达克指数在周三下午几无变动，当时联邦政府停摆生效[1][3] - 医疗保健板块是标普500指数中表现最佳的板块[1] 个股表现与公司动态 - 耐克公司股价上涨，因其季度盈利和营收超出预期，北美地区销售强劲[1][2][3] - 艾尔建公司股价领涨制药股，市场预期辉瑞公司与特朗普政府的交易可能为其他公司带来更多交易机会[1][3] - AES公司股价因报道称其将被贝莱德旗下全球基础设施合作伙伴以380亿美元收购而大幅上涨[2] - 科迪华公司股价暴跌，因该农产品生产商宣布将把种子和农药业务分拆为两家独立公司[2] - 网飞公司股价小幅下跌，此前特斯拉首席执行官埃隆·马斯克在社交媒体上表示取消其订阅并呼吁他人效仿[3] - 特斯拉公司股价上涨[3] 大宗商品与外汇市场 - 黄金价格攀升至创纪录新高[3] - 原油期货价格下跌[3] - 10年期美国国债收益率下滑[3] - 美元兑欧元、英镑和日元走弱[3] - 大多数主要加密货币交易价格走高[3]

Shares of Pfizer Inc. (NYSE:PFE) continue to head higher on Wednesday, a day after the company announced that it has secured a three-year grace period from President Donald Trump's tariffs on pharmaceuticals. This will enable Pfizer to offer its medication at significantly discounted prices compared to current rates.This news appears to have triggered a breakout in the shares. This can have bullish implications and may indicate that they will continue to move higher. This is why Pfizer is our Stock of the D ...

Key TakeawaysMajor automotive manufacturers General Motors (GM) and Toyota Motor North America reported significant sales increases in Q3 and September, respectively, with electric vehicle (EV) deliveries showing particularly strong growth.European stock markets closed notably higher, with healthcare stocks experiencing their largest daily surge since 2008 following a U.S. deal with Pfizer (PFE) to lower drug prices.U.S. stock markets rebounded with slight gains despite ongoing government shutdown concerns, ...

U.S. stock markets are demonstrating a remarkable resilience at midday on Wednesday, October 1st, 2025, largely shrugging off the impact of a fresh government shutdown and weaker-than-expected employment data. While futures initially dipped on the news of the shutdown, major indexes have pared early losses, with some even turning positive, as investors assess the broader economic landscape and upcoming policy decisions. This midday momentum suggests a market accustomed to political gridlock, though underlyi ...

Key Takeaways Amvuttra drives Alnylam's top line through expanded label and as patients switch from Onpattro.Givlaari, Oxlumo, and royalties from Leqvio add incremental revenues and global growth potential.Rare disease drugs delivered $236.8M in H1 2025 revenues, up 16% year over year.Alnylam Pharmaceuticals’ (ALNY) primary top-line driver is its newest drug, Amvuttra (vutrisiran), which is approved in the United States and the EU for treating the polyneuropathy of hereditary transthyretin-mediated (hATTR) ...